文献速递血脂与心血管预防

多效药片对比风险评估预防心血管疾病的成本效益

Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
PubMed 文献 · Heart · 2017-01-11

基于英国生物银行259146名40-69岁无症状参与者的微模拟模型,评估含辛伐他汀20mg及三种降压药的多效药片方案与不同风险阈值评估策略的成本效益。降低风险阈值至10%不具经济吸引力,每获得一个质量调整生命年需花费4万英镑;多效药片在药品价格降低时可能具有成本效益。

要点

  • 严格风险评估(风险超过20%时处方他汀和降压药)为最优策略,每万人获得123个质量调整生命年。
  • 将他汀处方风险阈值降至10%不具经济吸引力,每获得一个质量调整生命年需花费4万英镑。
  • 多效药片在年药品价格降至240英镑以下时从60岁开始成为最具成本效益的方案。

核心结论

  • 使用较低风险阈值的定期风险评估不太可能具有成本效益。
  • 若药品价格降低,多效药片将具有成本效益。

研究设计与样本

  • 开发微模拟模型,对259146名40-69岁无症状英国生物银行参与者进行终身预测,评估心血管疾病事件、糖尿病和死亡。
  • 评估多效药片方案(含辛伐他汀20mg、氨氯地平2.5mg、氯沙坦25mg和氢氯噻嗪12.5mg)与10年心血管疾病风险阈值为10%和20%的定期风险评估的增量成本和质量调整生命年。

主要发现

  • 较宽松的风险评估和多效药片方案预防了更多心血管疾病事件并获得更大生存获益,但这些获益被额外成本和每日用药的效用损失所抵消。
  • 将他汀处方风险阈值降至10%不具经济吸引力,每获得一个质量调整生命年需花费4万英镑。
  • 当年药品价格降至240英镑以下时,从60岁开始使用多效药片成为最具成本效益的方案。
  • 所有多效药片方案在价格低于50英镑时均节省成本。

关键数值与推荐

  • 风险阈值降至10%:每获得一个质量调整生命年需花费4万英镑。
  • 多效药片从60岁开始:年药品价格降至240英镑以下时最具成本效益。
  • 所有多效药片方案:价格低于50英镑时节省成本。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower cardiovascular risk. We assessed the cost-effectiveness of a population approach with a polypill including a statin (simvastatin 20 mg) and three antihypertensive agents (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) and periodic risk assessment with different risk thresholds. METHODS: We developed a microsimulation model for lifetime predictions of CVD events, diabetes, and death in 259 146 asymptomatic UK Biobank participants aged 40-69 years. We assessed incremental costs and quality-adjusted life-years (QALYs) for polypill scenarios with the same combination of agents and doses but differing for starting age, and periodic risk assessment with 10-year CVD risk thresholds of 10% and 20%. RESULTS: Restrictive risk assessment, in which statins and antihypertensives were prescribed when risk exceeded 20%, was the optimal strategy gaining 123 QALYs (95% credible interval (CI) -173 to 387) per 10 000 individuals at an extra cost of £1.45 million (95% CI 0.89 to 1.94) as compared with current practice. Although less restrictive risk assessment and polypill scenarios prevented more CVD events and attained larger survival gains, these benefits were offset by the additional costs and disutility of daily medication use. Lowering the risk threshold for prescription of statins to 10% was economically unattractive, costing £40 000 per QALY gained. Starting the polypill from age 60 onwards became the most cost-effective scenario when annual drug prices were reduced below £240. All polypill scenarios would save costs at prices below £50. CONCLUSIONS: Periodic risk assessment using lower risk thresholds is unlikely to be cost-effective. The polypill would become cost-effective if drug prices were reduced.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Ferket BS, Hunink MG, Khanji M, et al. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart. 2017. PMID: 28077465. doi:10.1136/heartjnl-2016-310529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。